By Counterforce Health Team in Strimvelis (autologous CD34+ ADA-SCID gene therapy) —

How to Get Strimvelis Gene Therapy Covered by Aetna CVS Health in Michigan: Complete Coding, Appeals & Authorization Guide

Answer Box: Getting Strimvelis Covered by Aetna CVS Health in Michigan

Strimvelis (autologous CD34+ gene therapy for ADA-SCID) requires prior authorization from Aetna CVS Health in Michigan. Use ICD-10 code D81.31 and HCPCS J3590 for billing. Submit genetic confirmation, enzyme testing showing <1% ADA activity, and proof of no suitable bone marrow donor. If denied, appeal internally within 180 days, then file external review with Michigan DIFS within 127 days. Start today: Call Aetna member services to verify gene therapy benefits and request rare disease case manager.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit Paths
  2. ICD-10 Mapping for ADA-SCID
  3. Product Coding: HCPCS, J-Codes, and NDC
  4. Clean Request Anatomy: Building Your Prior Authorization
  5. Frequent Pitfalls to Avoid
  6. Verification Steps with Aetna CVS Health
  7. Appeals Process in Michigan
  8. Quick Audit Checklist
  9. FAQ

Coding Basics: Medical vs. Pharmacy Benefit Paths

Strimvelis follows a unique pathway because it's administered exclusively at SR-TIGET in Milan, Italy, making it an international out-of-network treatment. Understanding which benefit applies affects your coding strategy.

Medical Benefit Path (Most Common)

  • When it applies: Hospital-based gene therapy administration
  • Key codes: ICD-10 D81.31, HCPCS J3590
  • Submission route: Provider submits via Aetna medical portal
  • Coverage team: Aetna's Gene-based, Cellular and Other Innovative Therapies (GCIT) program

Pharmacy Benefit Considerations

While Strimvelis isn't dispensed through traditional pharmacies, CVS Specialty Pharmacy (1-800-237-2767) may coordinate logistics for cell collection and transport to Milan.

Tip: Contact Aetna member services first to confirm which benefit applies to your specific plan. Some newer gene therapy benefits span both medical and pharmacy coverage.

ICD-10 Mapping for ADA-SCID

The correct diagnosis coding is critical for establishing medical necessity. ICD-10-CM code D81.31 specifically identifies "Severe combined immunodeficiency due to adenosine deaminase deficiency."

Primary Diagnosis Code

Code Description Documentation Required
D81.31 ADA-SCID Genetic confirmation of biallelic ADA mutations, enzyme activity <1% normal, T-cell lymphopenia

Supporting Codes (if applicable)

Code Description When to Use
D81.30 ADA deficiency, unspecified If SCID not confirmed but ADA deficiency present
D81.9 Combined immunodeficiency, unspecified Only if ADA-specific testing incomplete
Z87.891 Personal history of nicotine dependence If relevant to treatment history

Documentation Words That Support D81.31

Your medical records should include these specific terms:

  • "Severe combined immunodeficiency"
  • "ADA deficiency" or "adenosine deaminase deficiency"
  • "Biallelic pathogenic variants in ADA gene"
  • "T-cell lymphopenia with absent proliferative response"
  • "Recurrent opportunistic infections"

Product Coding: HCPCS, J-Codes, and NDC

Since Strimvelis lacks FDA approval in the US, it doesn't have a permanent HCPCS J-code. Here's how to code it properly:

Primary Billing Code

Code Type Code Description Units
HCPCS J3590 Unclassified biologics 1 (single administration)

Key Coding Details

  • No permanent J-code: CMS hasn't assigned a specific code as of 2025 quarterly updates
  • No US NDC: Manufactured exclusively at SR-TIGET in Milan
  • Billing description: Include full product name "Strimvelis (autologous CD34+ cells transduced to express ADA gene therapy)"
  • Cost estimate: €594,000 (~$650,000) for prior authorization
Note: Monitor CMS quarterly HCPCS updates for potential new codes. The next review cycles are Q1 and Q3 2025.

Clean Request Anatomy: Building Your Prior Authorization

A successful Strimvelis prior authorization requires specific clinical documentation. Here's the anatomy of a strong request:

Essential Components Checklist

Patient Information

  • Aetna member ID and group number
  • Patient demographics and contact information
  • Primary care physician and specialist information

Clinical Documentation

  • Genetic testing results: Biallelic pathogenic ADA variants
  • Enzyme activity: ADA levels <1% of normal range
  • Immunological workup: T-cell counts, proliferation studies
  • Infection history: Documented opportunistic infections
  • Growth/development: Failure to thrive documentation

Treatment Justification

  • HSCT eligibility: No suitable HLA-matched donor available
  • Alternative failures: PEG-ADA contraindication or failure
  • Urgency: Clinical deterioration without treatment
  • SR-TIGET acceptance: Formal eligibility letter from Milan

Administrative Details

  • Coding: ICD-10 D81.31, HCPCS J3590
  • Site of care: SR-TIGET, Milan, Italy
  • Treatment timeline: Projected dates for cell collection and administration
  • Cost estimate: Current pricing from SR-TIGET

Frequent Pitfalls to Avoid

These common mistakes can delay or derail your authorization:

Coding Errors

  • Wrong ICD-10: Using D81.9 (unspecified) instead of D81.31 (ADA-specific)
  • Missing J-code description: Failing to specify "Strimvelis" in J3590 billing
  • Incorrect units: Using multiple units instead of single administration

Documentation Gaps

  • Incomplete genetic testing: Missing pathogenicity assessment of ADA variants
  • Insufficient enzyme data: Providing relative percentages without absolute values
  • Vague HSCT ineligibility: General statements instead of specific donor search results

Timing Issues

  • Late submission: Waiting until clinical crisis to start authorization
  • Missing deadlines: Not tracking Aetna's response timeframes
  • Incomplete appeals: Failing to exhaust internal appeals before external review

Verification Steps with Aetna CVS Health

Before submitting your prior authorization, verify these key details:

Member Benefits Verification

  1. Call Aetna member services (number on ID card)
  2. Verify active coverage on proposed treatment dates
  3. Confirm gene therapy benefits and any annual/lifetime limits
  4. Check out-of-network coverage for international treatment
  5. Request rare disease case manager assignment

Provider Portal Checks

  • Access Aetna provider portal for current PA forms
  • Verify submission method (online vs. fax)
  • Check for any Strimvelis-specific requirements
  • Confirm expedited review criteria

CVS Specialty Coordination

Contact CVS Specialty Pharmacy (1-800-237-2767) to discuss:

  • Cell collection logistics in the US
  • Transport arrangements to Milan
  • Post-treatment monitoring coordination

Appeals Process in Michigan

If Aetna denies your Strimvelis authorization, Michigan offers robust appeal rights through a two-tier system.

Internal Appeals with Aetna

Timeline: 180 days from denial date
Process: Submit via Aetna member portal or mail
Decision time: 30 days (72 hours if expedited)

Required documents:

  • Original denial letter
  • Additional medical records
  • Updated physician letter of medical necessity
  • Peer-reviewed studies supporting Strimvelis efficacy

External Review with Michigan DIFS

Timeline: 127 days from Aetna's final denial
Authority: Michigan Department of Insurance and Financial Services
Decision time: 60 days standard, 72 hours expedited

How to file:

  • Online: DIFS PRIRA portal
  • Phone: 877-999-6442 (8am-5pm, M-F)
  • Forms: FIS 0018 form for paper submissions

Required documentation:

  • Aetna's final denial letter
  • Complete medical records
  • Physician letter stating urgency (for expedited review)
  • Insurance ID card and member information
Important: DIFS external review decisions are binding on Aetna. If you win, they must provide coverage as directed.

Quick Audit Checklist

Use this pre-submission checklist to catch errors:

Clinical Documentation Review

  • ICD-10 D81.31 matches diagnosis in medical records
  • ADA enzyme levels clearly documented as <1% normal
  • Genetic testing shows biallelic pathogenic variants
  • HSCT donor search results included
  • Prior treatment failures documented

Coding Accuracy Check

  • HCPCS J3590 with full Strimvelis description
  • Single unit billing (not multiple doses)
  • Cost estimate matches current SR-TIGET pricing
  • Site of care specified as Milan, Italy

Administrative Completeness

  • All required forms signed and dated
  • Attachments properly labeled and organized
  • Contact information current for all parties
  • Submission method confirmed with Aetna

When Treatment Gets Complex: Counterforce Health Support

Navigating gene therapy approvals can be overwhelming, especially for treatments like Strimvelis that require international coordination. Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to draft point-by-point rebuttals aligned with payer requirements.

Their platform pulls the right citations for medications—FDA labeling, peer-reviewed studies, and specialty guidelines—while tracking deadlines and procedural requirements for coverage determinations and external reviews. For complex cases like Strimvelis, having expert support can make the difference between approval and prolonged delays.

FAQ

Q: How long does Aetna prior authorization take for Strimvelis?
A: Standard decisions typically take 14-30 days. Request expedited review (72 hours) if clinical deterioration poses immediate risk.

Q: What if Strimvelis is considered experimental by Aetna?
A: Emphasize EMA approval, NICE recommendations, and published efficacy data. Counterforce Health can help craft appeals addressing experimental designations.

Q: Does step therapy apply to Strimvelis?
A: As an orphan drug for ultra-rare disease, step therapy requirements are typically waived. Document PEG-ADA failure or contraindication.

Q: Can I appeal if I'm denied for out-of-network treatment?
A: Yes. Emphasize that SR-TIGET is the only authorized treatment site worldwide. Request single-case agreement for network-level benefits.

Q: What happens if my child's condition worsens during appeals?
A: File for expedited internal and external appeals simultaneously. Michigan DIFS expedited reviews require physician documentation of health jeopardy.

Q: Are travel costs covered for Milan treatment?
A: Rarely. Some Aetna plans may cover lodging/travel if >100 miles from home, but verify specific benefits. Explore manufacturer assistance programs.

Q: How do I find a rare disease case manager at Aetna?
A: Call member services and specifically request assignment to their Gene-based, Cellular and Other Innovative Therapies (GCIT) program.

Q: What if Michigan DIFS upholds Aetna's denial?
A: You can appeal DIFS decisions in Michigan circuit court within 60 days, though this is uncommon for medically necessary treatments.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage processes and is not medical advice. Coverage decisions depend on individual circumstances, plan benefits, and clinical factors. Always consult with your healthcare provider and insurance company for personalized guidance. For assistance with complex appeals, consider consulting with healthcare coverage specialists.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.